HeartMate 3 LVAD Therapy

A treatment for those with advanced heart failure

HeartMate 3 LVAD has long-term proven outcomes

The HeartMate 3™ LVAD has been proven to help people with heart failure feel better and live longer.

Median survival exceeding 5 years1

Meaning that half or more of HeartMate 3 patients are still alive at 5 years.

 greater than 5 years

58.4% survival at 5 years1

Nearly 60% of the patients enrolled in the study were alive after 5 years.

 nearly 60%

Living with HeartMate 3 LVAD for Heart Failure

Listen to people tell their HeartMate 3 LVAD stories and how they are living their lives to the fullest.

Significant increase in six-minute walk distance.2

The six-minute walk test is a common way to test for your ability to perform daily physical activities. Patients who received the HeartMate 3 LVAD had a significant improvement in six-minute walk distance.

 Six minute walk test

Risk and Complication Information

There can be serious complications associated with LVAD therapy. It is important to understand these risks and discuss them with your doctor.

Other than the risks normally associated with major surgery and having general anesthesia, the potential complications of having a HeartMate LVAD are listed here.

Low Risk Profile For Continous-Flow LVAD

Results based on published data from multicenter experience and separate studies, which may involve different patient populations and other variables. Not a head-to-head comparison. Data presented for informational purposes only.

Additional Information

These materials are not intended to replace your doctor’s advice or information. For any questions or concerns you may have regarding the medical procedures, devices and/or your personal health, please discuss these with your physician.


  1. Mehra MR, Goldstein DJ, Cleveland JC, et al. Five-Year Outcomes in Patients With Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized Trial. JAMA. September 8, 2022. doi:10.1001/jama.2022.16197
  2. Schmitto JD, Shaw S, Garbade J, et al. Long-Term Results in Real World Patients Treated with HeartMate 3 LVAD for Advanced Heart Failure: Data from the ELEVATE Registry. European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting; October 8, 2022; Milan, Italy.

MAT-2406044 v1.0